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Abstract
The Luminex xTAG® respiratory viral panel (RVP) kit simultaneously detects and identifies 
multiple respiratory viruses including several subtypes of influenza A using a multiplex nucleic 
acid amplification test assay platform. The emitted fluorescence signal from the RVP assay 
provides qualitative information on the presence of a particular viral species in respiratory 
specimens. However, a quantitative assessment is preferred when monitoring environmental 
samples for respiratory viruses. In this study, we explored the potential use of the RVP kit as a 
semi-quantitative screening assay for influenza virus detection. The concentration- response of the 
RVP assay was modeled using four-parameter logistic (4-PL) fits of mean fluorescence intensity 
(MFI) versus dilute ranges of the influenza A matrix gene, seasonal influenza vaccine, and 2009 
H1N1 influenza vaccine. The goodness of fit of the 4-PL model was evaluated by comparing the 
copy number determined with the fitted model (observed copy number) with the copy number 
calculated from the dilution of the matrix DNA or vaccine (expected copy number). For the matrix 
DNA and 2009 H1N1 vaccine, the 4-PL model provided good fit for the influenza A RVP assay 
response over factors of 103 to 104. For seasonal influenza vaccine, the model provided good fit 
for RVP assay response to influenza A, influenza B, H1, and H3.
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Introduction
Taqman® real-time polymerase chain reaction (real-time PCR)-based techniques can be 
used to produce qualitative or quantitative results depending on the application. Diagnosis of 
influenza virus infection can be done using real-time PCR which can provide a qualitative 
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identification of the strain of influenza A subtype H1N1 virus causing the infection (World 
Health Organization, 2009). Techniques employing quantitative PCR (qPCR) have been 
developed for applications such as determination of viral contamination in water samples 
(Karim et al. 2009). For the determination of the relative contribution of various routes of 
exposure to influenza virus infection, quantitative assessment of surface contamination and 
air concentration in the environment can be done with qPCR using calibration with influenza 
virus vaccine (Blachere et al. 2007) or calibration with influenza matrix gene DNA 
(Lindsley et al. 2010). These qPCR techniques have been utilized to assess airborne 
concentrations in healthcare facilities (Blachere et al. 2009) or from cough samples 
(Lindsley et al. 2010).
The Luminex xTAG® respiratory viral panel (RVP) kit was developed to diagnose multiple 
respiratory viral infections simultaneously using a multiplex microbead-based technique 
(Krunic et al. 2007; Mahony 2007a; Mahony et al. 2007b; Merante et al. 2007). It has also 
been useful for recognizing the presence of unknown strains of the H1 subtype of influenza 
A (Ginocchio and St. George 2009a; Ginocchio et al. 2009b), where response to influenza A 
but no response to H1 or H3 subtypes showed the possible presence of a novel strain of H1 
influenza A. The RVP kit has been used in a qualitative manner in applications where 
response above a threshold is used to indicate the presence of a given viral species. In this 
proof of concept study, we measured the response of the RVP kit over a range of 
concentrations to explore its use for semi-quantitative or quantitative applications such as 
environmental monitoring. There was a limited amount of valid response data produced 
from this study since there were few RVP kits available. We therefore had to limit our 
evaluation to determining the response of the kits for a semi-quantitative interpretation of 
the data and areas for more work are given in the discussion.
Methods and materials
Reagents
The Luminex xTAG® RVP kits (TDAS RVP-1 version 1.11 Lot IK019C-0012) were 
manufactured by Luminex Molecular Diagnostics (Toronto, Ontario). The kits have all 
reagents needed to perform the assay. The RNase-free water was obtained from Invitrogen 
(Carlsbad, CA, USA).
Vaccine samples and cloned DNA
The influenza vaccines used in the production of response curves were 2005–2006 seasonal 
FluMist and 2009 H1N1 FluMist. The 2005–2006 seasonal FluMist was purchased from 
MedImmune Vaccine, Inc. (Gaithersburg, MD, USA). The 2005–2006 seasonal FluMist was 
a live, trivalent vaccine, composed of the A/New Caledonia/20/99 (H1N1), A/California/
7/2004 (H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361 /2002-like) strains. These strains 
were genetically altered to attenuated, cold-adapted, and temperature-sensitive phenotypes, 
which limits viral replication to the nasal pharynx. Each 0.5 mL dose has been formulated to 
contain approximately 107 TCID50 (106.5–107.5 median tissue culture infectious dose) per 
viral strain. In calculating concentrations, it was assumed that there are 2 × 107 copies of 
each virus in 1 mL of the undiluted vaccine so that H1 subtype, H3 subtype, and influenza B 
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were present at 2 × 107 copies/mL in the undiluted vaccine. However, the influenza A 
matrix gene (the influenza A response of the RVP kit) was present for both strains of 
influenza A so it was assumed to be 4 × 107 copies/mL in the undiluted vaccine. The 2009 
H1N1 FluMist vaccine was purchased from MedImmune and was monovalent (A/
California/7/2009 (H1N1) strain) with a 0.2 mL dose containing 107 TCID50 (106.5–107.5 
median tissue culture infectious dose). In calculations, it was assumed that the undiluted 
vaccine had 5 × 107 viral copies/mL.
The cloned influenza matrix gene M1 used in this pilot study was kindly provided by 
Francoise Blachere, NIOSH (Morgantown, WV, USA). The matrix DNA was diluted by 
factors of 10 from 10−4 to 10−12 with RNase-free water before running with the RVP kit and 
the concentration in the diluted samples was determined by multiplying the stock 
concentration by the dilution factor.
RNA extraction
The 2005–2006 seasonal and 2009 H1N1 vaccines were diluted by factors of 10 from 10−2 
to 10−8 with RNase-free water before RNA extraction and the concentration in the diluted 
samples was determined by multiplying the undiluted vaccine concentration by the dilution 
factor. The RNA was extracted from each diluted vaccine sample using a MagNA Pure 
Compact (MPC) (Roche Diagnostics, Indianapolis, IN, USA) with an RNA isolation kit 
(Roche 04 802 993 001) and a QIAamp MinElute Virus Spin kit (VSK) (product number 
57704, Qiagen, Valencia, CA, USA).
The MPC instrument performs the lysis, binding via magnetic beads to adsorb the RNA, 
washing, and elution of the RNA steps automatically. For the MPC extraction procedure, 
159 μL of the diluted vaccine was combined with 15.9 μL of phage MS2 internal control 
from the RVP kit and 175 μL of lysis buffer from the RNA isolation kit. The treated samples 
were loaded into the instrument and run with RNA Tissue-V3-1 program with the sample 
volume set at 350 μL. All reagents needed for the extraction were contained in kit cartridges 
that were loaded into the instrument. The final elution volume was set at 50 μL.
Manual isolation of viral RNA was performed using the VSK according to manufacturer 
instructions. For the VSK procedure, 182 μL of diluted vaccine was combined with 18.2 μL 
of the phage MS2 internal control from the RVP kit, 25 μL protease, and 200 μL lysis buffer 
and incubated for 15 min at 56°C. Ethanol was added to the treated sample and the RNA 
was adsorbed onto a membrane cartridge where it was washed several times with different 
kit buffers and ethanol and finally eluted into 50 μL. In calculating the concentration of 
recovered RNA from the MPC- and VSK-extracted samples, it was assumed that all the 
RNA from the diluted vaccines was extracted and was concentrated in the extraction 
procedure by a factor (initial sample volume/final elution volume) (159/50 for the MPC and 
182/50 for the VSK).
RNA and DNA determination using the RVP kit
The xTAG RVP kit was used in accordance to the manufacturer instructions. The thermal 
cycler employed was a model PTC-100, Programmable Thermal Controller (MJ Research, 
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Inc., Watertown, MA, USA). Detection of positive and negative bead signals was performed 
using a BioRad Bioplex model 100 system (BioRad, Hercules, CA, USA). Data collection 
with the Bioplex system used Luminex IS 100 2.3 software (Luminex Inc., Austin, TX, 
USA) with the xTAG RVP T-A kit software template. In addition to the extracted RNA 
from the diluted vaccines and the diluted matrix DNA samples, three negative controls 
(RNase-free water) and a run control (Lambda DNA supplied with the kit) were included in 
each run as specified by the kit instructions.
Data analysis
The batch file containing the data from the experiment was used to obtain mean 
fluorescence intensity (MFI) values for the diluted vaccine and matrix DNA samples. The 
dilution calculated copy number for each sample was calculated by multiplying the 
concentration as determined above by the volume of sample used in the reverse transcription 
PCR (RT-PCR) step of the assay, which was 5 μL. The MFI values for the diluted H1N1 and 
seasonal vaccine samples were normalized by calculating the average response from the 
internal control (phage MS2) for the vaccine samples. The MFI value for each individual 
diluted vaccine sample was multiplied by the ratio: average internal control MFI/individual 
sample internal control MFI. This helped to correct the differences in RNA extraction and 
well to well variations in the assay. The MFI versus dilution calculated copy number curve 
was fitted using four-parameter logistic model (4-PL, SigmaPlot, SPSS, Chicago, IL, USA). 
Assessment of the “goodness of fit” and the dynamic ranges of the assays were investigated 
by evaluating the fit of the standards data to the 4-PL model by “standards recovery” (Nix 
and Wild 2001), calculated by evaluating interpolated results from each 4-PL fit (observed 
copy number) and comparing it to the calculated copy number derived from dilution of the 
vaccine or matrix DNA (the expected copy number). The resultant data were analyzed for 
linearity by linear regression.
Results
Influenza A matrix gene DNA
Figure 1A shows the influenza A MFI response of the RVP kit as a function of the dilution 
calculated matrix gene DNA copy number. The assay response begins to rise when the 
dilution calculated copy number becomes greater than 1 (at 6.93 copies) and levels off at 
6.93 × 103 copies. The response curve was fitted with the 4-PL model from 6.93 × 10−2 
copies up to 6.93 × 104 copies and a fit with R2 > 0.999 was obtained. Observed copy 
number was calculated with the 4-PL model and was correlated with expected copy number 
from 6.93 to 6.93 × 103 copies as shown in Figure 1B.
2009 H1N1 vaccine
Figure 2 shows influenza A MFI response of the RVP kit as a function of calculated 
influenza A virus copies for the 2009 H1N1 influenza vaccine. The RNA in the diluted virus 
samples was extracted using both the MPC and VSK kits as described above. The assay 
response begins to rise before the dilution calculated virus copy number reaches 1 copy (at 
about 8 × 10−2 copies) and levels off at about 8 × 101 dilution calculated copies. Again this 
data was fitted with the 4-PL model with R2 > 0.999 obtained for both MPC and VSK 
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curves and the observed copy number calculated with the model correlated well with the 
expected copy number (R2 close to 1) over the range 8 × 10−2 to 8 × 101 dilution calculated 
copies. Also note that the MPC and VSK kits gave similar recoveries.
Seasonal influenza vaccine
Figure 3A shows influenza A MFI response of the RVP kit as a function of influenza A 
virus copies calculated from dilution for the 2005–2006 seasonal influenza vaccine. In a 
similar manner to the 2009 H1N1 vaccine, the influenza A response begins to rise before the 
calculated virus copy number reaches 1 copy (at about 8 × 10−2 copies) and levels off at 
about 8 × 101 calculated copies. This data was fitted with the 4-PL model (R2 > 0.999) and 
the copy number calculated with the model correlated well with the expected copy number 
(R2 close to 1). Both the MPC and VSK kits gave similar RNA recoveries.
Figure 3B and 3C show the influenza B, H1 influenza A subtype, and H3 influenza A 
subtype MFI response of the RVP kit as a function of influenza B, H1, and H3 dilution 
calculated copies for the 2005–2006 seasonal influenza vaccine extracted with the VSK and 
MPC kits, respectively. The influenza B MFI response of the RVP kit for both the VSK and 
MPC extracted samples began to increase at about 3 × 10−2 dilution calculated copies and 
leveled off at about 3 × 101 dilution calculated copies and the observed copy number 
calculated with the 4-PL model correlated well with the expected copy number calculated 
from dilution over this range. For H1 subtype, the MFI response of the RVP kit began 
increasing at about 3 × 10−1 dilution calculated copies and leveled off at 3 × 102 dilution 
calculated copies and the 4-PL model again provided good fit to this data. The H3 subtype 
response began to increase at about 3 × 100 dilution calculated copy number and had not 
completely leveled at 3 × 103, the highest dilution calculated copy number studied. Again 
the 4-PL model fit the data with high correlation of observed copy number with expected 
copy number.
Discussion
For a number of types of applications, such as environmental sampling, it is desirable to 
obtain semi-quantitative or quantitative information about the concentration of multiple viral 
species present in samples. The xTAG RVP assay is able to detect and identify multiple 
viral species, but the analysis software provides only qualitative interpretation of the 
measurements. In this pilot study, we have examined the response of the RVP kit to cloned 
influenza A matrix gene DNA and it was found that the influenza A response of the kit 
could be modeled with a 4-PL fit over a range of dilutions. The matrix gene DNA provided 
the most accurate measure of response since the concentration in the stock solution was 
calculated using UV spectroscopy. The RVP kit response from the matrix gene DNA did not 
increase until after the calculated copy number was greater than 1. For both vaccine 
samples, the influenza A response of the RVP kit response began to increase before the 
dilution calculated copy number reached 1 so the assumption that one tissue culture 
infectious dose (TCID) represents one viral genome copy apparently underestimates the 
actual copy number. However the 4-PL model provided a good fit of the influenza A RVP 
kit response for influenza A dilution calculated copy number for both the vaccines. 
Smith et al. Page 5













Additionally, the 4-PL model provided a good fit of influenza B, H1, and H3 RVP kit 
response to calculated copy number for the 2005–2006 seasonal vaccine samples. The RVP 
kit has no significant H1 response to 2009 H1N1 virus (Ginocchio and St. George, 2009a; 
Ginocchio et al. 2009b) so only influenza A response was observed for the 2009 H1N1 
vaccine in this study. The 4-PL fit is used for many immunoassays and is present in 
instrument software for immunoassay instruments such as BioPlex and Luminex instruments 
which can use Luminex IS 100 2.3 software. Several aspects of RVP kit performance could 
not be addressed in this study due to the limited availability of the RVP kits. The 
reproducibility of the response curves from the kits for the vaccine and matrix DNA samples 
could not be addressed because of limited data. It would be useful to estimate the limit of 
detection which would require more response data near the limit of detection in addition to 
the reproducibility data. In addition, the use of the RVP kit could be evaluated with 
environmental samples which were also evaluated with qPCR to compare the results from 
the two methods. These are areas for further work which could evaluate the ability of the 
RVP kits to produce quantitative data. The MPC automated and VSK manual RNA 
extraction procedures gave similar recoveries in this study but a more detailed comparison 
of the extraction procedures would require additional data. However, either procedure 
should provide useful data concerning the relative contribution of various sources of viral 
contamination.
One advantage of multiplexed methods is that multiple controls can be used with each 
sample. In the present study using the RVP kit, only the phage MS2 internal control is added 
to every extracted sample before RNA extraction. This provides a useful assessment of the 
extraction process. However, the addition of more controls could be useful if semi-
quantitative or quantitative results are desired. If the run control were added to every sample 
at the RT-PCR step, it could provide a response control in the midrange of the assay. Several 
other nonviral DNA sequences could be added at a lower concentration and a higher 
concentration than the run control. The RT-PCR primers and target specific primer 
extension primers would have to be added to the primer mix for these additional sequences 
along with appropriate bead sets for these additional controls. In this way, a relative 
calibration curve could be generated in every sample well and used to compensate for 
differences in assay response for different samples. This concept has been exploited 
previously in multiplex clinical immunoassays (Inverness Medical).
Conclusion
Our data suggest that the RVP kit has utility as a semi-quantitative assessment tool for 
determination of influenza A, influenza B, and the H1 and H3 subtypes of influenza A in 
environmental samples. It may also be useful for semi-quantitative determination of other 
respiratory viruses in these samples.
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(A) Influenza A response of Luminex xTAG RVP kit versus cloned influenza A matrix gene 
DNA dilution calculated copy number. The response is given as MFI as measured by the 
BioPlex reader. The copy number was calculated by multiplying the concentration of the 
diluted stock solution by the volume used in the RT-PCR step of the assay, which was 5 μL. 
The concentration of the diluted DNA was determined by multiplying the stock influenza A 
matrix gene concentration by the dilution factor.(B). Observed copy number versus expected 
copy number for the cloned influenza A matrix gene DNA. The observed copy number was 
calculated from the 4-PL fit of the influenza A response of the RVP kit for the cloned 
influenza A matrix gene DNA. The expected copy number was calculated from dilution of 
the stock influenza A matrix gene DNA.
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Influenza A response of Luminex xTAG RVP kit versus influenza A dilution calculated 
copy number for the 2009 H1N1 vaccine. The RNA from the samples was extracted with the 
VSK and MPC. The response is given as MFI as measured by the BioPlex reader. The copy 
number was calculated by multiplying the concentration of the diluted vaccine by the 
volume of sample used in the RT-PCR step of the assay, which was 5 μL. The concentration 
of the diluted vaccine was determined by multiplying the undiluted vaccine concentration by 
the dilution factor.
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(A) Influenza A response of the RVP kit versus influenza A dilution calculated copy number 
for the 2005–2006 seasonal influenza vaccine. The RNA from the samples was extracted 
with the VSK and MPC. The response is given as MFI as measured by the BioPlex reader. 
The copy number was calculated by multiplying the concentration of the diluted vaccine by 
the volume of sample used in the RT-PCR step of the assay, which was 5 μL. The 
concentration of the diluted vaccine was determined by multiplying the undiluted vaccine 
concentration by the dilution factor. (B). Influenza B, H1 influenza A subtype, and H3 
influenza A subtype response of the RVP kit versus dilution calculated copy number for the 
2005–2006 seasonal influenza vaccine for samples extracted with VSK. The response is 
given as MFI as measured by the BioPlex reader. The copy number was calculated by 
multiplying the concentration of the diluted vaccine by the volume of sample used in the 
RT-PCR step of the assay, which was 5 μL. The concentration of the diluted vaccine was 
determined by multiplying the undiluted vaccine concentration by the dilution factor. (C). 
Influenza B, H1 influenza A subtype, and H3 influenza A subtype response of Luminex 
xTAG RVP kit versus dilution calculated copy number for the 2005–2006 seasonal 
influenza vaccine for samples extracted with MPC. The response is given as MFI as 
measured by the BioPlex reader. The copy number was calculated by multiplying the 
concentration of the diluted vaccine by the volume of sample used in the RT-PCR step of 
the assay, which was 5 μL. The concentration of the diluted vaccine was determined by 
multiplying the undiluted vaccine concentration by the dilution factor.
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